Search research articles
Contact Us
Filters
Showing results (331-340 of 418) with videos related to
Page
of 42
Sort By:
Frontiers in Oncology
|
August 22, 2025
Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers
Giulia Scotto, Anna Galatà, Robert Fruscio, et al.
Frontiers in Oncology
|
October 3, 2022
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial
Andrea Antonuzzo, Carla Ida Ripamonti, Fausto Roila, et al.
European Urology
|
October 10, 2022
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
Francesca Vignani, Rosa Tambaro, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
December 4, 2013
Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control
Nicla La Verde, Anna Moretti, Gabriella Farina, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 7, 2013
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study
Alessandro Morabito, Vittorio Gebbia, Massimo Di Maio, et al.
Tumori
|
October 13, 2011
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)
Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.
Recenti Progressi in Medicina
|
December 28, 2020
Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients
Donatella Marino, Chiara Baratelli, Giovanni Guida, et al.
Expert Review of Anticancer Therapy
|
November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Clinical Genitourinary Cancer
|
January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study
Daniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
July 15, 2016
The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations
Vincenzo De Sanctis, Ashraf T Soliman, Heba Elsedfy, et al.
Page
of 42
Search research articles
Search
Showing results (331-340 of 418) with videos related to
Sort By:
Page
of 42
Frontiers in Oncology
|
August 22, 2025
Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers
Giulia Scotto, Anna Galatà, Robert Fruscio, et al.
Frontiers in Oncology
|
October 3, 2022
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial
Andrea Antonuzzo, Carla Ida Ripamonti, Fausto Roila, et al.
European Urology
|
October 10, 2022
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
Francesca Vignani, Rosa Tambaro, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
December 4, 2013
Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control
Nicla La Verde, Anna Moretti, Gabriella Farina, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 7, 2013
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study
Alessandro Morabito, Vittorio Gebbia, Massimo Di Maio, et al.
Tumori
|
October 13, 2011
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)
Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.
Recenti Progressi in Medicina
|
December 28, 2020
Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients
Donatella Marino, Chiara Baratelli, Giovanni Guida, et al.
Expert Review of Anticancer Therapy
|
November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Clinical Genitourinary Cancer
|
January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study
Daniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
July 15, 2016
The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations
Vincenzo De Sanctis, Ashraf T Soliman, Heba Elsedfy, et al.
Page
of 42